Bryan Fellman

Bryan Fellman

Auto-generated profile, based on publicly available information

Bryan Fellman

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2017 in Cancer
Verified
Journal Article
Open access
PDF file
FKFumi Kawakami
Fumi Kawakami
KSKanishka Sircar
Kanishka Sircar
JRJaime Rodriguez‐Canales
Jaime Rodriguez‐Canales
BFBryan M. Fellman
Bryan M. Fellman
DUDiana L. Urbauer
Diana L. Urbauer
JKJose A. Karam
Jose A. Karam
BACKGROUND: The immune profile of sarcomatoid renal cell carcinoma (sRCC), including the programmed cell death ligand 1 (PD‐L1) and programmed cell death 1 (PD‐1) status, has not been well characterized.METHODS: An immunohistochemical digital analysis of PD‐L1, PD‐1, CD4, and CD8 was performed on nephrectomy specimens from 118 sRCC patients and 92 nonsarcomatoid clear cell renal cell carcinoma (ccRCC) patients. The clinical characteristics of the population were compared between sRCC and ccRCC. Overall survival was estimated, and comparisons were made between PD‐L1–positive and PD‐L1–negative groups as well as tumor‐infiltrating lymphocyte (TIL)–high and TIL‐low groups.RESULTS: The PD‐L1 H‐score of sRCC (mean, 3.7; range, 0‐192.1) was significantly higher than the score of grade 4 ccRCC (P = .001), and 41.3% of sRCC cases showed a PD‐L1 H‐score ≥ 10. The PD‐1–positive cell density was significantly higher in sRCC versus ccRCC within the tumor and at the invasive front. The intratumoral CD8‐positive cell density was significantly higher in sRCC versus ccRCC. Forty‐one percent in the sarcomatoid component of sRCC and 8% in the epithelioid component of sRCC had an adaptive immune resistance phenotype (PD‐L1–positive and TIL‐positive), whereas only 1% in ccRCC had the type I phenotype.CONCLUSIONS: sRCC showed higher PD‐L1 expression and higher PD‐1– and CD8‐positive cell density than grade 4 ccRCC. The results indicate a notable immunosuppressive environment in sRCC. Despite advances in the treatment of advanced‐stage renal cell carcinoma, sRCC still has a poor prognosis. This work describes highly immunosuppressive characteristics of sRCC in comparison with an appropriate ccRCC control. The results suggest PD‐1/PD‐L1 blockade therapy as a potential therapeutic approach for sRCC. Cancer 2017;123:4823‐31. © 2017 American Cancer Society.


24 February 2021 in Cancers
Verified
Journal Article
Open access
PDF file
JHJeffrey How
Jeffrey How
AJAmir A. Jazaeri
Amir A. Jazaeri
BFBryan Fellman
Bryan Fellman
MDMolly S. Daniels
Molly S. Daniels
SPSuzanna Penn
Suzanna Penn
MYMelinda Yates
Melinda Yates
New therapies, such as poly-ADP ribose polymerase inhibitors (PARPi), and immunotherapy treatments have generated great interest in enhancing individualized molecular profiling of epithelial ovarian cancer (EOC) to improve management of the disease. In EOC patients, putative biomarkers for homologous recombination deficiency (HRD), microsatellite instability (MSI), and tumor mutational burden (TMB) were characterized and correlated with survival outcomes. A series of 300 consecutive EOC patients were enrolled. Patients underwent neoadjuvant chemotherapy (n = 172) or primary cytoreductive surgery (n = 128). Molecular profiling and survival analyses were restricted to the primary cytoreductive surgery cohort due to tissue availability. All patients underwent germline testing for HRD- and MSI-related gene mutations. When sufficient tissue was available, screening for somatic BRCA1/2 mutations, BRCA1 promoter methylation, HRD score (a measure of genomic instability), MSI, and TMB testing were performed. HRD score ≥33 was associated with improved overall survival on multivariable analysis. In the era of biomarker-driven clinical care, HRD score ≥33 may be a useful adjunctive prognostic tool and should be evaluated in future studies to predict PARPi benefits.

7 October 2023 in Investigative Radiology
Verified
Journal Article
Closed access
YLYuan-Mao Lin
Yuan-Mao Lin
IPIwan Paolucci
Iwan Paolucci
JSJessica Albuquerque Marques Silva
Jessica Albuquerque Marques Silva
COCaleb S. O'COnnor
Caleb S. O'COnnor
BFBryan M. Fellman
Bryan M. Fellman
BOBruno C. Odisio
Bruno C. Odisio
Objectives: The aim of this study was to investigate the prognostic value of 3-dimensional minimal ablative margin (MAM) quantified by intraprocedural versus initial follow-up computed tomography (CT) in predicting local tumor progression (LTP) after colorectal liver metastasis (CLM) thermal ablation. Materials and Methods: This single-institution, patient-clustered, tumor-based retrospective study included patients undergoing microwave and radiofrequency ablation between 2016 and 2021. Patients without intraprocedural and initial follow-up contrast-enhanced CT, residual tumors, or with follow-up less than 1 year without LTP were excluded. Minimal ablative margin was quantified by a biomechanical deformable image registration method with segmentations of CLMs on intraprocedural preablation CT and ablation zones on intraprocedural postablation and initial follow-up CT. Prognostic value of MAM to predict LTP was tested using area under the curve and competing-risk regression model. Results: A total of 68 patients (mean age ± standard deviation, 57 ± 12 years; 43 men) with 133 CLMs were included. During a median follow-up of 30.3 months, LTP rate was 17% (22/133). The median volume of ablation zone was 27 mL and 16 mL segmented on intraprocedural and initial follow-up CT, respectively (P < 0.001), with corresponding median MAM of 4.7 mm and 0 mm, respectively (P < 0.001). The area under the curve was higher for MAM quantified on intraprocedural CT (0.89; 95% confidence interval [CI], 0.83–0.94) compared with initial follow-up CT (0.66; 95% CI, 0.54–0.76) in predicting 1-year LTP (P < 0.001). An MAM of 0 mm on intraprocedural CT was an independent predictor of LTP with a subdistribution hazards ratio of 11.9 (95% CI, 4.9–28.9; P < 0.001), compared with 2.4 (95% CI, 0.9–6.0; P = 0.07) on initial follow-up CT. Conclusions: Ablative margin quantified on intraprocedural CT significantly outperformed initial follow-up CT in predicting LTP and should be used for ablation endpoint assessment.

17 April 2023 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
EKEleonora Khlebus
Eleonora Khlebus
VVVeena K. Vuttaradhi
Veena K. Vuttaradhi
TWThomas Welte
Thomas Welte
NKNamrata Khurana
Namrata Khurana
JCJoseph Celestino
Joseph Celestino
RHRobert Hillman
Robert Hillman
Adult-type granulosa cell tumors (aGCT) are rare ovarian sex cord tumors with few effective treatments for recurrent disease. The objective of this study was to characterize the tumor microenvironment (TME) of primary and recurrent aGCTs and to identify correlates of disease recurrence. Total RNA sequencing (RNA-seq) was performed on 24 pathologically confirmed, cryopreserved aGCT samples, including 8 primary and 16 recurrent tumors. After read alignment and quality-control filtering, DESeq2 was used to identify differentially expressed genes (DEG) between primary and recurrent tumors. Functional enrichment pathway analysis and gene set enrichment analysis was performed using “clusterProfiler” and “GSVA” R packages. TME composition was investigated through the analysis and integration of multiple published RNA-seq deconvolution algorithms. TME analysis results were externally validated using data from independent previously published RNA-seq datasets. A total of 31 DEGs were identified between primary and recurrent aGCTs. These included genes with known function in hormone signaling such as LHCGR and INSL3 (more abundant in primary tumors) and CYP19A1 (more abundant in recurrent tumors). Gene set enrichment analysis revealed that primarily immune-related and hormone-regulated gene sets expression was increased in recurrent tumors. Integrative TME analysis demonstrated statistically significant depletion of cancer-associated fibroblasts in recurrent tumors. This finding was confirmed in multiple independent datasets. Implications: Recurrent aGCTs exhibit alterations in hormone pathway gene expression as well as decreased infiltration of cancer-associated fibroblasts, suggesting dual roles for hormonal signaling and TME remodeling underpinning disease relapse.

1 December 2019 in JCO Clinical Cancer Informatics
Verified
Journal Article
Open access
ESEileen H. Shinn
Eileen H. Shinn
GBGordon Broderick
Gordon Broderick
BFBryan Fellman
Bryan Fellman
AJAinslee Johnson
Ainslee Johnson
EWElizabeth Wieland
Elizabeth Wieland
WSWilliam Fraser Symmans
William Fraser Symmans
PURPOSE: Nearly 40% of patients with breast cancer discontinue their adjuvant oral endocrine treatment (ET). We measured discontinuation rates of ET at a comprehensive cancer center. We then used an iterative approach to model patterns of determinants associated with discontinuation of ET. METHODS: Patients with nonmetastatic breast cancer receiving active adjuvant ET were approached by nurse practitioners to complete an anonymous survey at one time point. We simulated a prospective model by iteratively regressing adverse effects onto adherence status across windowed time periods of 2 to 3 consecutive years, bootstrapping the smaller group of nonadherent patients and subsampling the larger adherent group. RESULTS: From February to April 2013, 216 participants were enrolled in the study. Forty patients (18.5%) reported that they had discontinued ET during the first 5 years of ET, and an additional four patients (1.9%) missed > 20% of their doses. Using two-sided significance tests, simulations showed that all 13 ET adverse effects and reasons for discontinuation were significantly related to discontinuation at some time point during ET. Worry about ET cost (odds ratio [OR], 1.79), emotional distress (OR, 1.72), and bone and joint pain (OR, 1.69) were the three most impactful reasons for discontinuation, with varying patterns of influence over time. CONCLUSION: These analyses provide preliminary evidence that there are varying patterns of discontinuation of ET. Although some reasons for discontinuation exerted a steady influence over the 6-year ET trajectory (ie, bone and joint pain), other reasons, such as cost, cognitive complaints, and general dislike of pills, became more important in the later years of ET.